Fig. 3From: Utility of in vitro release testing (IVRT) to assess ‘sameness’ of 1% clotrimazole creams for use as a biowaiverRelease rate profiles from SA and CA Canesten.® 1% CLZ (R1 and R2), CA-marketed 1% CLZ generic cream (CA1), and extemporaneously compounded creams T1 and T2 (n = 6)Back to article page